Q-omics provides the consensus-scored DUT profile across patient tissues and cancer cell-line models. DUT expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, DUT is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, DUT RNA expression shows 19,145 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LUAD, HNSC, and ACC as cancer lineages where DUT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DUT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DUT survival associations across molecular data types. DUT RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DUT RNA expression–survival associations across cancer types. High DUT expression shows unfavorable associations in LUAD, ACC, MESO, COAD and UVM, but favorable associations in KIRC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for DUT RNA expression.
This table summarizes DUT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DUT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DUT shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, BLCA, LUSC and ESCA. The HNSC box plot shows higher DUT RNA expression in tumor versus normal tissue (log2 FC = +1.019, t-test p < 0.001).
This table shows molecular features associated with DUT in patient tissues and cancer cell lines. In patient samples, DUT shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, DUT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
